News
Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice
In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary arterial hypertension in real-world practice were published from the international EXPERT registry, which also included Czech patients. The safety profile of the therapy was consistent with the findings of previous clinical studies.
Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics
Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused…
Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades…
To what extent can the actual level of ALP, ALT, or bilirubin differ from the measured value?
A physician who bases clinical decisions on laboratory-determined values of biological parameters…
Treatment of Motor Symptoms of Parkinson's Disease
Parkinson's disease (PD) is one of the few neurodegenerative disorders for which effective…
Liposomal Pegylated Irinotecan in the Treatment of Pancreatic Tumors
Combined treatment with liposomal pegylated irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV)…
New Treatment Option for Metastatic Pancreatic Cancer – Pegylated Liposomal Irinotecan
The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its…
What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment are insufficient...
Can Co-administration of Dabigatran with Antiretroviral Drugs Be Effective and Safe?
In 2019, the first results regarding the concurrent use of antiretroviral drugs and oral…
The Future and Prospects of Type 2 Diabetes Therapy: Can We Fully Cure It with Endoscopy or Genetics?
Diabetes mellitus (DM) cannot be cured, but it can be successfully treated... Will we rewrite this…